EUVIMEDEUVIMED entdecken
Crossref

Appraisal of Olezarsen for Treatment of Hypertriglyceridemia

Nasser Mikhail

International Journal of Endovascular Treatment and Innovative Techniques · 2024

DOI: 10.61797/ijetit.v5i1.334 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Endovascular Treatment and Innovative Techniques, 2024. Verfasst von Nasser Mikhail. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Olezarsen is antisense antinucleotide under investigation that inhibits synthesis of apolipoprotein C3 (ApoC3) resulting in reduction of plasma triglycerides levels. In a phase 3 clinical trial of patients having familial chylomicronemia syndrome (FCS) with extreme hypertriglyceridemia at baseline (mean plasma triglycerides 2,630 mg/dl), olezarsen 80 mg administered subcutaneously every 4 weeks decreased triglycerides by 43.5 percentage points (95% CI, 69.1 to 17.9; P

Zitieren

APA

Mikhail, N. (2024). Appraisal of Olezarsen for Treatment of Hypertriglyceridemia. International Journal of Endovascular Treatment and Innovative Techniques. https://doi.org/10.61797/ijetit.v5i1.334

Vancouver

Mikhail N. Appraisal of Olezarsen for Treatment of Hypertriglyceridemia. International Journal of Endovascular Treatment and Innovative Techniques. 2024. doi:10.61797/ijetit.v5i1.334

BibTeX
@article{Mikhail2024,
  author = {Mikhail, Nasser},
  title = {Appraisal of Olezarsen for Treatment of Hypertriglyceridemia},
  journal = {International Journal of Endovascular Treatment and Innovative Techniques},
  year = {2024},
  doi = {10.61797/ijetit.v5i1.334}
}
Kostenlos starten →